





PHARMACEUTICAL 2023

CNBX Pharmaceuticals Inc.
Rank 434 of 446



The relative strengths and weaknesses of CNBX Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CNBX Pharmaceuticals Inc. compared to the market average is the variable Property and Equipment, increasing the Economic Capital Ratio by 80% points. The greatest weakness of CNBX Pharmaceuticals Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 321% points.

The company's Economic Capital Ratio, given in the ranking table, is -422%, being 465% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	198
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	2,443
Liabilities, Non-Current	0
Other Assets	176
Other Compr. Net Income	-669
Other Expenses	782
Other Liabilities	0
Other Net Income	13
Other Revenues	0
Property and Equipment	437
Research and Development	1,183
Selling, General and Administrative Expense	1,771

Output Variable	Value in 1000 USD
Assets	811
Liabilities	2,443
Expenses	3,736
Revenues	0
Stockholders Equity	-1,632
Net Income	-3,723
Comprehensive Net Income	-4,058
Economic Capital Ratio	-422%